Recent progress of matrix metalloproteinase (MMP) research and its clinical application for cancer therapy

Y. Otani, M. Fujii, T. Kubota, M. Kitajima, Y. Okada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading the extracellular matrix, including collagens, laminin, proteoglycan and fibronectin. In some human cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. An imbalance between MMPs and the tissues inhibitor of metalloproteinases (TIMPs) may play a significant role in the invasive phenotype of cancers. Although TIMPs have been shown to inhibit tumor metastasis in some in vivo models, they are not suitable for pharmacologic applications due to their short half-life in vivo and large molecular size. In this paper, recent advances in MMP research and reports of clinical applications of synthetic MMP inhibitors for cancer patients are reviewed.

Original languageEnglish
Pages (from-to)957-964
Number of pages8
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume25
Issue number7
Publication statusPublished - 1998 Jun

Fingerprint

Matrix Metalloproteinases
Tissue Inhibitor of Metalloproteinases
Matrix Metalloproteinase Inhibitors
Research
Neoplasms
Neoplasm Metastasis
Endopeptidases
Laminin
Proteoglycans
Therapeutics
Fibronectins
Extracellular Matrix
Half-Life
Zinc
Collagen
Phenotype
Membranes
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Recent progress of matrix metalloproteinase (MMP) research and its clinical application for cancer therapy. / Otani, Y.; Fujii, M.; Kubota, T.; Kitajima, M.; Okada, Y.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 25, No. 7, 06.1998, p. 957-964.

Research output: Contribution to journalArticle

Otani, Y. ; Fujii, M. ; Kubota, T. ; Kitajima, M. ; Okada, Y. / Recent progress of matrix metalloproteinase (MMP) research and its clinical application for cancer therapy. In: Gan to kagaku ryoho. Cancer & chemotherapy. 1998 ; Vol. 25, No. 7. pp. 957-964.
@article{a43e2948259045e9b31fee99a9fbc9ba,
title = "Recent progress of matrix metalloproteinase (MMP) research and its clinical application for cancer therapy",
abstract = "The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading the extracellular matrix, including collagens, laminin, proteoglycan and fibronectin. In some human cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. An imbalance between MMPs and the tissues inhibitor of metalloproteinases (TIMPs) may play a significant role in the invasive phenotype of cancers. Although TIMPs have been shown to inhibit tumor metastasis in some in vivo models, they are not suitable for pharmacologic applications due to their short half-life in vivo and large molecular size. In this paper, recent advances in MMP research and reports of clinical applications of synthetic MMP inhibitors for cancer patients are reviewed.",
author = "Y. Otani and M. Fujii and T. Kubota and M. Kitajima and Y. Okada",
year = "1998",
month = "6",
language = "English",
volume = "25",
pages = "957--964",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - Recent progress of matrix metalloproteinase (MMP) research and its clinical application for cancer therapy

AU - Otani, Y.

AU - Fujii, M.

AU - Kubota, T.

AU - Kitajima, M.

AU - Okada, Y.

PY - 1998/6

Y1 - 1998/6

N2 - The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading the extracellular matrix, including collagens, laminin, proteoglycan and fibronectin. In some human cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. An imbalance between MMPs and the tissues inhibitor of metalloproteinases (TIMPs) may play a significant role in the invasive phenotype of cancers. Although TIMPs have been shown to inhibit tumor metastasis in some in vivo models, they are not suitable for pharmacologic applications due to their short half-life in vivo and large molecular size. In this paper, recent advances in MMP research and reports of clinical applications of synthetic MMP inhibitors for cancer patients are reviewed.

AB - The matrix metalloproteinases (MMPs) are a family of secreted and membrane-bound zinc-endopeptidases. These enzymes are capable of degrading the extracellular matrix, including collagens, laminin, proteoglycan and fibronectin. In some human cancers, a positive correlation has been demonstrated between MMP expression and the likelihood of developing metastasis. An imbalance between MMPs and the tissues inhibitor of metalloproteinases (TIMPs) may play a significant role in the invasive phenotype of cancers. Although TIMPs have been shown to inhibit tumor metastasis in some in vivo models, they are not suitable for pharmacologic applications due to their short half-life in vivo and large molecular size. In this paper, recent advances in MMP research and reports of clinical applications of synthetic MMP inhibitors for cancer patients are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=18144437947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144437947&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 957

EP - 964

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -